• License includes 50/50 profit share and additional payments of up to $185 million dependent on achieving clinical development and sales milestones, and subject to certain reductions
• Phase 3 clinical trial results for CPP-1X/sul in patients with Familial Adenomatous Polyposis expected in 1H 2019

Continue reading→

California Cryobank is the nation’s leading frozen sperm and egg donor bank. Continue reading→

The Center for Entrepreneurial Innovation is opening up enrollment for its third Mastermind Learning course, VentureStack. This year-long program will begin on September 6th.Continue reading→

Paradigm Diagnostics Inc. raised $8.9 million in venture capital to market its genetic profiling test aimed at personalized medicine. The round was led by San Diego-based Mesa Verde Venture Partners, along with New York-based Science Ventures LLC. Both have invested in Paradigm in the past. The investment brings the total amount raised by the company to $19.8 million since the bioscience firm’s first $3.5 million raise in December 2016. Read the latest filing here.Continue reading→

Clinical Partners Join Alliance to Advance Precision Medicine in OncologyContinue reading→

Symposium caps 8-week internship of real-life biomedical research sponsored by Helios Education FoundationContinue reading→

The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich Parkinson’s clinical trials. The purpose of this enrichment biomarker is to serve as a measurement that can be used to select people with Parkinson’s who are most suitable to take part in clinical trials.Continue reading→